Hvhist-M Tablet is a combination medication containing Montelukast 120mg and Fexofenadine 10mg, formulated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, works by blocking leukotriene D4 in the lungs and bronchial tubes, thereby reducing inflammation, bronchoconstriction, and mucus production. Fexofenadine, a second-generation antihistamine, selectively inhibits peripheral H1 receptors, alleviating symptoms like sneezing, itching, watery eyes, and nasal congestion without causing significant sedation. The synergistic action of Montelukast and Fexofenadine provides comprehensive relief from allergy symptoms by targeting multiple pathways involved in the allergic response. Hvhist-M Tablet is indicated for patients requiring effective control of seasonal and perennial allergic rhinitis, as well as chronic idiopathic urticaria. It is generally well-tolerated, with a favorable safety profile; common adverse effects may include headache, dizziness, and gastrointestinal discomfort. This combination therapy offers the convenience of dual-action treatment in a single dosage form, improving patient compliance. Hvhist-M should be used under medical supervision, with dosage adjustments considered based on clinical response and patient tolerance. It is contraindicated in individuals with known hypersensitivity to its components.